These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 15262298)

  • 1. Management of metabolic syndrome: aspirin.
    Shields TM; Hennekens CH
    Endocrinol Metab Clin North Am; 2004 Sep; 33(3):577-93, vii. PubMed ID: 15262298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
    Hennekens CH; Schneider WR
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin to prevent heart attack and stroke: what's the right dose?
    Dalen JE
    Am J Med; 2006 Mar; 119(3):198-202. PubMed ID: 16490462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspirin use in the prevention of cardiovascular events.
    Crutcher JM; Mallonee S; Daniels C
    J Okla State Med Assoc; 2007 Oct; 100(10):383-7. PubMed ID: 18085095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiplatelet therapy in the treatment of atherothrombotic disease: considering the evidence.
    Aronow WS
    Geriatrics; 2007 Apr; 62(4):12-24. PubMed ID: 17408314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination antiplatelet agents for secondary prevention of ischemic stroke.
    Vande Griend JP; Saseen JJ
    Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.
    Tangelder MJ; Frison L; Weaver D; Wilcox RG; Bylock A; Emanuelsson H; Held P; Oldgren J
    Am Heart J; 2008 Feb; 155(2):382-7. PubMed ID: 18215612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
    Bhatt DL; Flather MD; Hacke W; Berger PB; Black HR; Boden WE; Cacoub P; Cohen EA; Creager MA; Easton JD; Hamm CW; Hankey GJ; Johnston SC; Mak KH; Mas JL; Montalescot G; Pearson TA; Steg PG; Steinhubl SR; Weber MA; Fabry-Ribaudo L; Hu T; Topol EJ; Fox KA;
    J Am Coll Cardiol; 2007 May; 49(19):1982-8. PubMed ID: 17498584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiplatelet agents and randomized trials.
    Diener HC
    Rev Neurol Dis; 2007; 4(4):177-83. PubMed ID: 18195669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
    Fox KA; Mehta SR; Peters R; Zhao F; Lakkis N; Gersh BJ; Yusuf S;
    Circulation; 2004 Sep; 110(10):1202-8. PubMed ID: 15313956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
    Reaume KT; Regal RE; Dorsch MP
    Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin in cardiovascular disease.
    Sexton RC
    Tenn Med; 2001 Jun; 94(6):208-10. PubMed ID: 11402787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knowledge of cardiovascular risk factors and awareness of non-pharmacological approach for risk prevention in young survivors of acute myocardial infarction. The cardiovascular risk prevention project "Help Your Heart Stay Young".
    Migliaresi P; Celentano A; Palmieri V; Pezzullo S; Martino S; Bonito M; Guillaro B; Brancati C; Di Minno G
    Nutr Metab Cardiovasc Dis; 2007 Jul; 17(6):468-72. PubMed ID: 17379491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    Bhatt DL; Topol EJ;
    Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient: a neurologist's view.
    Gebel JM
    J Am Coll Cardiol; 2005 Sep; 46(5):752-5. PubMed ID: 16139120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention.
    Chapman MJ
    Pharmacol Ther; 2007 Jan; 113(1):184-96. PubMed ID: 17070923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
    Kirshner HS
    Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers.
    Mikkelsson J; Eskola M; Nikus K; Karhunen PJ; Niemela K
    Ann Med; 2008; 40(4):296-302. PubMed ID: 18428022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing aspirin use in patients with Type 2 diabetes in the UKPDS.
    Cull CA; Neil HA; Holman RR
    Diabet Med; 2004 Dec; 21(12):1368-71. PubMed ID: 15569143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.